Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
25/09/2026 16:47
BRIEF-Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027 Sept 25 (Reuters) - Newron Pharmaceuticals SpA NWRN.S:
NEWRON PROVIDES UPDATE ON PHASE 3 ENIGMA-TRS 2 STUDY
NEWRON PHARMACEUTICALS SPA - TOPLINE DATA FROM ENIGMA-TRS 1 EXPECTED IN Q1 2027
NEWRON PHARMACEUTICALS SPA - U.S. CLINICAL HOLD REMAINS IN PLACE FOR ENIGMA-TRS 2 STUDY
NEWRON PHARMACEUTICALS SPA: INITIATING EXPANSION OF CLINICAL SITES AND ENROLLMENT FOR ENIGMA-TRS 2 IN EUROPE, ASIA AND LATIN AMERICA
Source text: ID:nGNXwlLPJ
Further company coverage: NWRN.S
((((Reuters.Briefs@thomsonreuters.com));))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study